Interojo Co

Interojo Co EBIT Growth

The Year-over-Year EBIT Growth of Interojo Co (119610.KQ) as of Nov 20, 2026 is 234.97 %. In the previous year, Year-over-Year EBIT Growth was 12.02 % — a change of 1,855.47% (higher).

EBIT Growth

234.97 %

YoY

1,855.47%

Last updated:

Year-over-Year EBIT Growth of Interojo Co is 2025 234.97 % . Year-over-Year EBIT Growth of Interojo Co was 2024 12.02 % . It decreases by 1,855.47% higher compared to the previous year.

The Interojo Co EBIT Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Growth
Date
EBIT Growth
Jan 1, 2018
-29.33 KRW
Jan 1, 2019
32.07 KRW
Jan 1, 2020
-33.06 KRW
Jan 1, 2021
86.01 KRW
Jan 1, 2022
10.56 KRW
Jan 1, 2023
-83.32 KRW
Jan 1, 2024
12.02 KRW
Jan 1, 2025
234.97 KRW
The Interojo Co EBIT Growth history
YEAREBIT GrowthYoY
234.97 %+1,855.47%
12.02 %-114.42%
-83.32 %-889.21%
10.56 %-87.72%
86.01 %-360.17%
-33.06 %-203.08%
32.07 %-209.34%
-29.33 %-837.32%
3.98 %-90.77%
43.08 %-49.74%
85.71 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Interojo Co Stock analysis

What does Interojo Co do? Interojo Co Ltd manufactures and sells contact lenses including silicone hydrogel lenses, sodium hyaluronate lenses, frequent replacement lenses, conventional lenses, toric lenses, multifocal vision lenses, color lenses, therapy and bandage lenses, and rigid gas permeable (RGP) contact lenses along with solutions. The company distributes its products in domestic and overseas markets, targeting both retail consumers and healthcare providers who purchase lenses for patient use. Its product range caters to diverse vision correction needs, from standard to specialized medical applications, with solutions supporting lens care and usage. The firm's primary revenue streams come from the sale of contact lenses and associated solutions to customers in both domestic and international markets. Products like silicone hydrogel lenses and RGP contact lenses represent key offerings for everyday wear and specialized vision correction, while therapy and bandage lenses serve medical applications requiring professional oversight. The company's domestic market presence complements its overseas distribution, ensuring broad accessibility across different customer segments. Interojo Co Ltd's business model focuses on direct sales of its comprehensive product portfolio to end-users and healthcare institutions. The company's product lines address various vision correction scenarios, from routine daily use with frequent replacement lenses to advanced medical needs with therapy lenses. By maintaining a diverse range of contact lenses and solutions, the company serves both consumer and professional markets without relying on third-party partnerships or additional services. Interojo Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Interojo Co stock

Year-over-Year EBIT Growth of Interojo Co is 234.97 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year EBIT Growth Interojo Co since 2006 – with annual values, charts, and detailed analysis.

EBIT growth measures the percentage change in operating earnings. It shows whether a company's core operations are becoming more profitable.

To evaluate Year-over-Year EBIT Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBIT Growth.

Year-over-Year EBIT Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBIT Growth's Interojo Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Interojo Co

All Key Metrics — Interojo Co